## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.5% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (45% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($563.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View**
- Source: Insider Monkey | 20251230T230944 | Bullish | Relevance: 100%
- Bank of America has raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650, maintaining a Buy rating, anticipating a biopharma recovery in 2026. The firm believes easing headwinds and a rebound in R&D spending will benefit companies like Thermo Fisher. This outlook also follows Thermo Fisher's recent acquisition of Clario for up to $9.4 billion, aimed at strengthening its clinical trial research business.

**2. Thermo Fisher Q4 2025 Earnings: Forecast, Date, and Analyst Outlook - News and Statistics**
- Source: IndexBox | 20251230T110944 | Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. (TMO) is projected to announce its fiscal fourth-quarter earnings for 2025 on January 29, 2026, with analysts anticipating a 5.6% increase in EPS to $6.44 per share. Despite underperforming the S&P 500 Index and the Health Care Select Sector SPDR Fund over the past year due to challenges in China, pricing pressures, and cautious spending, the company's Q3 results surpassed expectations. Analysts currently hold a "Strong Buy" consensus rating for TMO, with an average price target indicating an 8.9% upside.

**3. Thermo Fisher Scientific Inc. $TMO Shares Sold by Mirova US LLC**
- Source: MarketBeat | 20251230T130818 | Somewhat-Bullish | Relevance: 100%
- Mirova US LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in Q3, now holding 660,789 shares valued at $320.5 million, making TMO its 12th largest holding. Thermo Fisher Scientific recently exceeded quarterly earnings and revenue estimates, issued strong FY2025 EPS guidance, and authorized a $5 billion share buyback program. The company also declared a quarterly dividend of $0.43 per share, although insiders were net sellers of approximately $86.5 million in stock during the quarter.

**4. First American Bank Buys 6,814 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251230T124252 | Bullish | Relevance: 100%
- First American Bank increased its stake in Thermo Fisher Scientific Inc. by 30.0% during the 3rd quarter, acquiring an additional 6,814 shares. This makes Thermo Fisher Scientific the 25th largest position in the bank's portfolio, valued at $14.306 million. Several other institutional investors also modified their holdings in the medical research company.

**5. Oak Harvest Investment Services Invests $3.47 Million in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251230T122052 | Somewhat-Bullish | Relevance: 100%
- Oak Harvest Investment Services recently invested $3.47 million in Thermo Fisher Scientific Inc. by purchasing 7,158 shares. The company reports strong Q3 earnings, beating estimates with EPS of $5.79 and revenue of $11.12 billion, and has authorized a $5 billion share buyback program. Despite significant insider selling over the past three months, analysts maintain a "Moderate Buy" consensus with an average price target of $616.60.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $219.2B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 23.7 |
| Current P/E | 25.7 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.3% to 1.5% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.87), confirming momentum. RSI neutral at 58. Volume at 45% of 20MA suggests lack of conviction. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.48% (CS: 74) | Neutral |
| RSI_14 | 57.6 | Neutral |
| MACD Histogram | 0.87 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.017x | Above |
| vs SMA200 | 1.203x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $583.51
- **Stop Loss:** $563.73 (3.4% risk)
- **Target:** $603.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $38,511.66
- **Portfolio %:** 38.51%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*